NEW YORK – ERS Genomics said on Monday that is has signed a licensing agreement with Japan-based Daiichi Sankyo providing the pharmaceutical company with access to ERS's CRISPR-Cas9 genome editing technology intellectual property.
Dublin-based ERS Genomics was founded to provide access to CRISPR-Cas9 intellectual property held by Emmanuelle Charpentier. This CRISPR IP is shared between her, Jennifer Doudna and the University of California, and the University of Vienna, and is separate from genome editing patents held by the Broad Institute.